Breakthrough therapy status for erdafitinib in bladder cancer
The US Food and Drug Administration has granted Breakthrough Therapy designation for erdafitinib in the treatment of urothelial cancer.
The drug is being developed by US healthcare giant Johnson & Johnson’s (NYSE: JNJ) group of Janssen companies. Last year J&J included erdafitinib (JNJ42756493) in a list of late-stage blockbuster products projected to be filed for regulatory approvals between 2017 and 2021.
Erdafitinib was discovered by UK-based Astex Pharmaceuticals and Janssen as part of a 2008 exclusive worldwide collaboration and licence agreement to identify novel, small molecule inhibitors of fibroblast growth factor receptor (FGFR) kinase, including for the treatment of cancer. Janssen is responsible for the clinical development and commercialization of all products arising from this collaboration. In October 2013 Astex became a wholly-owned subsidiary of Japan’s Otsuka Pharmaceutical (TYO: 4578), under an around $900 million takeover deal.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze